Aarti Drugs Limited reported a decline in financial performance for Q2 and H1 FY25, with revenue down 7% to Rs. 599.8 crores and net profit down 12% to Rs. 35.0 crores, highlighting challenges in the API market. The company completed a buyback of 6,65,000 shares at Rs. 900 each.